Zora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing
Zora and Mayo Medical Laboratories has signed Collaborate on Plasma Ceramides Testing. The test will be launched in summer, and is used to predict adverse cardiovascular events in patients with coronary artery disease (CAD).
“We hope the test will improve the evaluation of individuals at risk for cardiovascular disease” says Jeff Meeusen, Ph.D., co-director of the Cardiovascular Laboratory Medicine Group at Mayo Clinic.
“Collaborating with Mayo Clinic is a great opportunity to make our diagnostic discoveries widely available for the benefit of patients and physicians,” says Reini Hurme, Ph.D., CEO of Zora Biosciences Oy. “This collaborative research will address unmet needs in cardiovascular disease assessment.”
Read the news here.